NATCO PHARMA
Back to Income Statement
|
NATCO PHARMA Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹4,430 Cr | ₹3,999 Cr | ₹2,707 Cr | ₹1,945 Cr | ₹2,052 Cr |
What is the latest Revenue of NATCO PHARMA ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹4,430 Cr |
| Mar2024 | ₹3,999 Cr |
| Mar2023 | ₹2,707 Cr |
| Mar2022 | ₹1,945 Cr |
| Mar2021 | ₹2,052 Cr |
How is Revenue of NATCO PHARMA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,430 Cr | 10.77 | |
| Mar2024 | ₹3,999 Cr | 47.72 | |
| Mar2023 | ₹2,707 Cr | 39.20 | |
| Mar2022 | ₹1,945 Cr | -5.23 | |
| Mar2021 | ₹2,052 Cr | - | |
Compare Revenue of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹15,135.7 Cr | -1% | -7.2% | -29.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹408,991.0 Cr | 0.1% | -3.2% | -2.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹162,371.0 Cr | -1.5% | -7.3% | 2.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹135,229.0 Cr | -1.3% | -0.7% | 24.4% | Stock Analytics | |
| CIPLA | ₹108,441.0 Cr | 1.5% | -8.1% | -6.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,407.0 Cr | 3.2% | 5.6% | 3.1% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -1% |
-7.2% |
-29.2% |
| SENSEX | 2.9% |
-1.1% |
8.5% |
You may also like the below Video Courses